全文获取类型
收费全文 | 5922篇 |
免费 | 34篇 |
专业分类
电工技术 | 5篇 |
综合类 | 1篇 |
化学工业 | 143篇 |
金属工艺 | 12篇 |
机械仪表 | 14篇 |
建筑科学 | 22篇 |
矿业工程 | 3篇 |
能源动力 | 18篇 |
轻工业 | 77篇 |
水利工程 | 7篇 |
石油天然气 | 3篇 |
无线电 | 37篇 |
一般工业技术 | 110篇 |
冶金工业 | 5427篇 |
原子能技术 | 2篇 |
自动化技术 | 75篇 |
出版年
2023年 | 5篇 |
2022年 | 13篇 |
2021年 | 43篇 |
2020年 | 21篇 |
2019年 | 14篇 |
2018年 | 27篇 |
2017年 | 26篇 |
2016年 | 19篇 |
2015年 | 13篇 |
2014年 | 29篇 |
2013年 | 28篇 |
2012年 | 40篇 |
2011年 | 36篇 |
2010年 | 27篇 |
2009年 | 35篇 |
2008年 | 19篇 |
2007年 | 18篇 |
2006年 | 16篇 |
2005年 | 12篇 |
2004年 | 14篇 |
2003年 | 16篇 |
2002年 | 8篇 |
2001年 | 3篇 |
2000年 | 4篇 |
1999年 | 164篇 |
1998年 | 1655篇 |
1997年 | 900篇 |
1996年 | 644篇 |
1995年 | 331篇 |
1994年 | 317篇 |
1993年 | 331篇 |
1992年 | 39篇 |
1991年 | 61篇 |
1990年 | 78篇 |
1989年 | 67篇 |
1988年 | 62篇 |
1987年 | 82篇 |
1986年 | 59篇 |
1985年 | 57篇 |
1983年 | 11篇 |
1982年 | 31篇 |
1981年 | 34篇 |
1980年 | 39篇 |
1979年 | 2篇 |
1978年 | 8篇 |
1977年 | 144篇 |
1976年 | 336篇 |
1975年 | 10篇 |
1965年 | 1篇 |
1955年 | 5篇 |
排序方式: 共有5956条查询结果,搜索用时 866 毫秒
991.
RG Miller JH Petajan WW Bryan C Armon RJ Barohn JC Goodpasture RJ Hoagland GJ Parry MA Ross SC Stromatt 《Canadian Metallurgical Quarterly》1996,39(2):256-260
Preclinical investigations indicated that recombinant human ciliary neurotrophic factor (rhCNTF) may have potential as therapy for amyotrophic lateral sclerosis (ALS). We evaluated the safety and efficacy of rhCNTF in a prospective, double-blind, placebo-controlled trial in 570 patients with ALS. Patients were randomized to receive 0.5, 2, or 5 micrograms/kg/day rhCNTF, or placebo, for 6 months. The primary efficacy end point was the change from baseline to the last on-treatment value of a combination megascore for limb strength (maximum voluntary isometric contraction) and pulmonary function. Secondary end points included individual arm and leg megascores, pulmonary function tests, an activities-of-daily-living outcome measure, and survival. The four treatment groups were similar at baseline with respect to age, sex, disease duration, and muscle strength values. At all doses tested, rhCNTF had no beneficial effect on the primary or secondary end points. Certain adverse events, as follows, appeared to be dose related: injection site reactions, cough, asthenia, nausea, anorexia, weight loss, and increased salivation. There was an increased number of deaths at the highest dose level. rhCNTF had no beneficial effect on any measure of ALS progression. There were increased adverse events in the 5 micrograms/kg group and increased deaths. 相似文献
992.
993.
994.
M Packer WS Colucci JD Sackner-Bernstein CS Liang DA Goldscher I Freeman ML Kukin V Kinhal JE Udelson M Klapholz SS Gottlieb D Pearle RJ Cody JJ Gregory NE Kantrowitz TH LeJemtel ST Young MA Lukas NH Shusterman 《Canadian Metallurgical Quarterly》1996,94(11):2793-2799
BACKGROUND: Carvedilol has improved the symptomatic status of patients with moderate to severe heart failure in single-center studies, but its clinical effects have not been evaluated in large, multicenter trials. METHODS AND RESULTS: We enrolled 278 patients with moderate to severe heart failure (6-minute walk distance, 150 to 450 m) and a left ventricular ejection fraction < or = 0.35 at 31 centers. After an open-label, run-in period, each patient was randomly assigned (double-blind) to either placebo (n = 145) or carvedilol (n = 133; target dose, 25 to 50 mg BID) for 6 months, while background therapy with digoxin, diuretics, and an ACE inhibitor remained constant. Compared with placebo, patients in the carvedilol group had a greater frequency of symptomatic improvement and lower risk of clinical deterioration, as evaluated by changes in the NYHA functional class (P = .014) or by a global assessment of progress judged either by the patient (P = .002) or by the physician (P < .001). In addition, treatment with carvedilol was associated with a significant increase in ejection fraction (P < .001) and a significant decrease in the combined risk of morbidity and mortality (P = .029). In contrast, carvedilol therapy had little effect on indirect measures of patient benefit, including changes in exercise tolerance or quality-of-life scores. The effects of the drug were similar in patients with ischemic heart disease or idiopathic dilated cardiomyopathy as the cause of heart failure. CONCLUSIONS: These findings indicate that, in addition to its favorable effects on survival, carvedilol produces important clinical benefits in patients with moderate to severe heart failure treated with digoxin, diuretics, and an ACE inhibitor. 相似文献
995.
996.
Crystal structure of the kinesin motor domain reveals a structural similarity to myosin 总被引:2,自引:0,他引:2
FJ Kull EP Sablin R Lau RJ Fletterick RD Vale 《Canadian Metallurgical Quarterly》1996,380(6574):550-555
Kinesin is the founding member of a superfamily of microtubule based motor proteins that perform force-generating tasks such as organelle transport and chromosome segregation. It has two identical approximately 960-amino-acid chains containing an amino-terminal globular motor domain, a central alpha-helical region that enables dimer formation through a coiled-coil, and a carboxy-terminal tail domain that binds light chains and possibly an organelle receptor. The kinesin motor domain of approximately 340 amino acids, which can produce movement in vitro, is much smaller than that of myosin (approximately 850 amino acids) and dynein (1,000 amino acids), and is the smallest known molecular motor. Here, we report the crystal structure of the human kinesin motor domain with bound ADP determined to 1.8-A resolution by X-ray crystallography. The motor consists primarily of a single alpha/beta arrowhead-shaped domain with dimensions of 70 x 45 x 45 A. Unexpectedly, it has a striking structural similarity to the core of the catalytic domain of the actin-based motor myosin. Although kinesin and myosin have virtually no amino-acid sequence++ identity, and exhibit distinct enzymatic and motile properties, our results suggest that these two classes of mechanochemical enzymes evolved from a common ancestor and share a similar force-generating strategy. 相似文献
997.
998.
999.
1000.
The amorphous nucleoplasm of the germinal vesicle nucleus of Xenopus laevis oocytes has been selectively extracted under conditions which leave the nuclear formed elements morphologically intact. The nucleoplasm contains about 97% of the total nuclear proteins and on SDS-polyacrylamide gels some 68 polypeptides can be distinguished. On the basis of solubility differences, the nucleoplasmic proteins can be classified into two categories. The first consists of soluble or easily solubilized proteins which comprise about 34 polypeptides making up 87% of the nucleoplasm. A few of these proteins show electrophoretic mobilities similar to those of soluble proteins of the cytoplasm, but most are unique to the nucleus. The residual 13% of the nucleoplasmic proteins are tightly bound to a nucleoplasmic gel and can be extracted only by solubilizing the gel. The solubility characteristics of the proteinaceous gel suggest a complex held together by salt, nonpolar, hydrogen, and possibly disulfide bonding. Some 34 polypeptides can be distinguished in this gel fraction, including prominent and highly enriched polypeptides of about 115,000 and 46,000 daltons. The relatively soluble fraction of the nucleoplasm does not contain informofers and contains little or no nucleic acid. Evidence is presented that if histones are present in the germinal vesicle, they can comprise no more than about 8% of the total protein. The possibility is discussed that the unique polypeptides of the nucleoplasm may be sequestered there by selective adsorption to or in the nuclear gel. 相似文献